Tom Fleming (Kerry South, Independent)
Link to this: Individually | In context

Question 740: To ask the Minister for Health if the cystic fibrosis drug Kayldeco is covered under the medical card scheme; and if he will make a statement on the matter. [34448/12]

Tom Fleming (Kerry South, Independent)
Link to this: Individually | In context

Question 741: To ask the Minister for Health if the cystic fibrosis drug Katldeco is covered under the long term illness scheme; and if he will make a statement on the matter. [34449/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

I propose to take Questions Nos. 740 and 741 together.

Ivacaftor (Kalydeco) received a positive opinion from the Committee for Medicinal Products for Human Use at EU level in May 2012. Marketing authorisation issued by the EU Commission is anticipated in due course. Should the manufacturers make an application for inclusion of the product on the GMS and community drugs schemes, that application shall be considered in accordance with the relevant criteria.